Becton Dickinson (NYSE:BDX) insider Alexandre Conroy sold 20,128 shares of Becton Dickinson stock in a transaction dated Monday, May 21st. The stock was sold at an average price of $228.74, for a total value of $4,604,078.72. Following the transaction, the insider now owns 35,583 shares of the company’s stock, valued at approximately $8,139,255.42. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Shares of NYSE:BDX traded down $0.04 during trading on Thursday, reaching $226.21. 35,064 shares of the stock were exchanged, compared to its average volume of 1,177,013. Becton Dickinson has a 12 month low of $185.33 and a 12 month high of $248.39. The stock has a market cap of $60.26 billion, a PE ratio of 23.84, a P/E/G ratio of 1.57 and a beta of 1.15. The company has a quick ratio of 1.12, a current ratio of 1.70 and a debt-to-equity ratio of 1.07.
Becton Dickinson (NYSE:BDX) last issued its quarterly earnings data on Thursday, May 3rd. The medical instruments supplier reported $2.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.63 by $0.02. Becton Dickinson had a positive return on equity of 14.27% and a negative net margin of 0.46%. The company had revenue of $4.22 billion during the quarter, compared to analysts’ expectations of $4.12 billion. During the same quarter in the previous year, the company posted $2.30 earnings per share. The business’s revenue was up 42.2% on a year-over-year basis. equities research analysts expect that Becton Dickinson will post 10.99 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 29th. Stockholders of record on Friday, June 8th will be issued a dividend of $0.75 per share. This represents a $3.00 dividend on an annualized basis and a dividend yield of 1.33%. The ex-dividend date is Thursday, June 7th. Becton Dickinson’s dividend payout ratio is presently 31.65%.
A number of equities analysts recently commented on BDX shares. ValuEngine upgraded Becton Dickinson from a “hold” rating to a “buy” rating in a report on Wednesday, April 18th. Zacks Investment Research cut Becton Dickinson from a “buy” rating to a “hold” rating in a report on Tuesday, March 6th. Piper Jaffray Companies reiterated an “overweight” rating and set a $260.00 price target (up previously from $223.00) on shares of Becton Dickinson in a report on Tuesday, February 6th. Morgan Stanley lifted their price target on Becton Dickinson from $245.00 to $250.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 7th. Finally, Citigroup upgraded Becton Dickinson from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $237.00 to $251.00 in a report on Tuesday, April 10th. Five analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company’s stock. Becton Dickinson currently has an average rating of “Buy” and an average price target of $241.19.
Large investors have recently modified their holdings of the company. Legacy Advisors LLC boosted its stake in shares of Becton Dickinson by 7,000.0% in the fourth quarter. Legacy Advisors LLC now owns 497 shares of the medical instruments supplier’s stock valued at $106,000 after buying an additional 490 shares during the period. Amica Retiree Medical Trust boosted its stake in shares of Becton Dickinson by 325.0% in the fourth quarter. Amica Retiree Medical Trust now owns 510 shares of the medical instruments supplier’s stock valued at $109,000 after buying an additional 390 shares during the period. Almanack Investment Partners LLC. bought a new stake in shares of Becton Dickinson in the fourth quarter valued at approximately $109,000. FTB Advisors Inc. boosted its stake in shares of Becton Dickinson by 114.2% in the fourth quarter. FTB Advisors Inc. now owns 544 shares of the medical instruments supplier’s stock valued at $116,000 after buying an additional 290 shares during the period. Finally, BDO Wealth Advisors LLC boosted its stake in shares of Becton Dickinson by 361.6% in the first quarter. BDO Wealth Advisors LLC now owns 577 shares of the medical instruments supplier’s stock valued at $125,000 after buying an additional 452 shares during the period. Institutional investors own 84.45% of the company’s stock.
Becton Dickinson Company Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.
Receive News & Ratings for Becton Dickinson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and related companies with MarketBeat.com's FREE daily email newsletter.